News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,333 Results
Type
Article (41343)
Company Profile (265)
Press Release (688709)
Multimedia
Podcasts (93)
Webinars (21)
Section
Business (204840)
Career Advice (2032)
Deals (35583)
Drug Delivery (128)
Drug Development (81512)
Employer Resources (173)
FDA (16505)
Job Trends (14980)
News (346810)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (46)
Adcomms (26)
Allergies (171)
Alliances (49579)
ALS (210)
Alzheimer's disease (1785)
Antibody-drug conjugate (ADC) (441)
Approvals (16878)
Artificial intelligence (652)
Autoimmune disease (283)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (745)
Cancer (5766)
Cardiovascular disease (466)
Career advice (1724)
Career pathing (42)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (888)
Cervical cancer (47)
Clinical research (70755)
Collaboration (2034)
Company closure (5)
Compensation (1384)
Complete response letters (79)
COVID-19 (2740)
CRISPR (107)
C-suite (1106)
Cystic fibrosis (152)
Data (7788)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (84)
Diabetes (585)
Diagnostics (6917)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (314)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91961)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119398)
Executive appointments (1076)
FDA (20195)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1704)
Gene editing (232)
Generative AI (55)
Gene therapy (715)
GLP-1 (1050)
Government (4729)
Grass and pollen (6)
Guidances (408)
Healthcare (18990)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (286)
Immuno-oncology (93)
Indications (189)
Infectious disease (3077)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16666)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (757)
Lymphoma (429)
Machine learning (59)
Management (59)
Manufacturing (1033)
MASH (185)
Medical device (13920)
Medtech (14038)
Mergers & acquisitions (20155)
Metabolic disorders (1492)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (412)
Neuropsychiatric disorders (105)
Neuroscience (3283)
Neurotech (1)
NextGen: Class of 2026 (6522)
Non-profit (4530)
Now hiring (77)
Obesity (698)
Opinion (286)
Ovarian cancer (219)
Pain (250)
Pancreatic cancer (296)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (666)
Peanut (62)
People (59545)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22056)
Phase 2 (31171)
Phase 3 (23197)
Pipeline (8522)
Policy (314)
Postmarket research (2568)
Preclinical (9395)
Press Release (64)
Prostate cancer (294)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1066)
Real estate (5968)
Recruiting (70)
Regulatory (25359)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3639)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (63)
Vaccines (1088)
Venture capital (108)
Weight loss (450)
Women's health (124)
Worklife (20)
Date
Today (175)
Last 7 days (925)
Last 30 days (3509)
Last 365 days (30264)
2026 (12082)
2025 (30171)
2024 (35212)
2023 (40073)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39651)
Australia (6501)
California (13164)
Canada (3735)
China (1328)
Colorado (564)
Connecticut (571)
Delaware (401)
Europe (85798)
Florida (1966)
Georgia (421)
Hawaii (3)
Idaho (62)
Illinois (1045)
India (88)
Indiana (597)
Iowa (23)
Japan (530)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1581)
Massachusetts (9393)
Michigan (359)
Minnesota (712)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3460)
New Mexico (29)
New York (3436)
North Carolina (1669)
North Dakota (9)
Northern California (6595)
Ohio (396)
Oklahoma (23)
Oregon (41)
Pennsylvania (2648)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5189)
Tennessee (209)
Texas (2086)
United States (46428)
Utah (392)
Vermont (1)
Virginia (316)
Washington D.C. (80)
Washington State (1054)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,333 Results for "arcellx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Gilead wipes out most of Arcellx workforce
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.
May 7, 2026
·
1 min read
·
Angela Gabriel
Press Releases
Gilead Extends Tender Offer to Acquire Arcellx
April 2, 2026
·
8 min read
Press Releases
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026
·
7 min read
Press Releases
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
April 17, 2026
·
8 min read
Press Releases
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
February 23, 2026
·
12 min read
Mergers & acquisitions
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026.
February 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
February 5, 2026
·
8 min read
Press Releases
Arcellx Provides Third Quarter 2025 Financial Results
November 5, 2025
·
4 min read
Press Releases
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
January 22, 2026
·
6 min read
Press Releases
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
November 19, 2025
·
2 min read
1 of 73,034
Next
